CBD oil without THC for agitation in Alzheimer’s dementia
Part of Brain & nervous system, Mental health clinical trials.
This trial studies whether a THC-free CBD oil softgel can reduce agitation in people with Alzheimer’s-related dementia. It compares CBD to a control to see if it improves difficult behaviors and is safe over the study period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 50 or older.
- You have a diagnosis of Alzheimer’s dementia, or mixed Alzheimer’s dementia (Alzheimer’s plus another type).
- Your thinking test score (MMSE) is between 4 and 28.
- You have agitation/aggression symptoms that score above 3 on the NPI (a behavior checklist).
- A family/caregiver must live with you or spend at least 4 hours per day with you, and both you and your caregiver can speak and read English well enough for consent.
- If you take donepezil, rivastigmine, galantamine, or memantine, your dose has been stable for at least 30 days (or you stopped it at least 15 days ago).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a CBD medication can help reduce agitation in people with Alzheimer's disease. It's for adults 55 and older who have significant agitation and mild to moderate dementia.
This Phase 3 trial studies whether nabilone can reduce agitation (restlessness, anger, or difficult behavior) in people with Alzheimer’s dementia. It’s designed for older adults who already have agitation despite standard dementia care.
This trial tests an investigational drug called BMS-986368 to see if it can safely reduce agitation in people with Alzheimer's disease. You may be able to join if you have Alzheimer's with confirmed biomarkers and experience agitation that has been going on for at least 4 weeks.
This study tests an experimental drug (KarXT) to see if it safely reduces agitation in people with Alzheimer's disease. It may help if you or your loved one experiences restlessness, aggression, or irritability related to Alzheimer's.
This trial studies treatment for troubling nighttime restlessness and agitation in people with Alzheimer’s disease. It may help improve sleep and nighttime comfort and reduce nighttime behavior problems.
This trial tests a new drug called CM383 in people with mild cognitive impairment or mild Alzheimer's disease. The goal is to see if it can help slow down memory loss.
Hear when a new Dementia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.